Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777 | 0.81 | KDM1A (0.35) | SLC6A4HTR7 | |
| SCHEMBL6655779 | 0.81 | NR3C1 (0.33) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL27947259 | 0.81 | CA1 (0.47) | SLC6A2SLC6A4SLC6A3MAOBHTR7 | |
| SCHEMBL13970077 | 0.79 | SLC5A2 (0.38) | SLC6A2SLC6A4SLC6A3CYP2D6MAPT | |
| SCHEMBL4620798 | 0.78 | SLC5A2 (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4622359 | 0.78 | LOXL2 (0.46) | SLC6A2SLC6A4SLC6A3MAOB | |
| SCHEMBL1686 | 0.78 | FADS1 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6ACHE | |
| SCHEMBL4622856 | 0.78 | SLC5A2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22043585 | 0.78 | FADS1 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6ACHE | |
| SCHEMBL5936386 | 0.78 | MEN1 (0.38) | MAOBMAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119215-B2 | Production method of citalopram, intermediate therefor and production method of the intermediate | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20020095051-A1 | Production method of citalopram, intermediate therefor and production method of the intermediate | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095051-A1 | Production method of citalopram, intermediate therefor and production method of the intermediate | INMT, FAR1, CYP51A1 | SLC6A2 309/4885SLC6A4 46/4885SLC6A3 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.